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Abbreviations 
AD, Alzheimer’s disease; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; 
BDNF, brain derived neurotrophic factor; CFC, context fear conditioning; CS, context-shock; 
DS, Down syndrome;  FDR, false discovery rate; FvN, failed vs. normal learning; GABAA, 
gamma-aminobutyric acid; GAD2, glutamic acid decarboxylase-2; Hsa21, human chromosome 
21; ID, intellectual disability; IEF, iso-electric focusing; IEG, immediate early gene; KEGG, 
Kyoto Encyclopedia of Genes and Genomes; LTD, long term depression; LM, learning/memory; 
LTP, long term potentiation; MAPK, Mitogen-Activated Protein Kinase; Mmu16, mouse 
chromosome 16; MTOR, Mammalian Target of Rapamycin;  MWM, Morris Water Maze; NAM, 
negative allosteric modulator; NMDA, N-methyl-d-aspartate; NRvN, normal learning + 
RO4038581 vs normal learning + vehicle; RvF, partially rescued vs. failed learning; SC, shock-
context. 
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Abstract 
 Down syndrome (DS), trisomy of human chromosome 21, is the most common genetic 
cause of intellectual disability (ID). There are no treatments for the cognitive deficits. The 
Ts65Dn is a partial trisomy mouse model of DS that shows learning and memory (LM) 
impairments and other abnormalities relevant to those seen in DS. Many drugs and small 
molecules have been shown to rescue the LM deficits, but little is known about the associated 
molecular responses. Here, patterns of protein expression are described in hippocampus of 
Ts65Dn and euploid littermate controls exposed to a battery of LM and behavior tests with and 
without chronic treatment with the GABAA receptor α5 subunit-selective negative allosteric 
modulator, RO4938581, that rescued LM deficits. Levels of 91 proteins/protein modifications, 
selected for relevance to LM and synaptic plasticity, were measured: 44 of 52 abnormalities 
present in vehicle-treated Ts65Dn were corrected by RO4938581. Superimposing protein data 
onto the molecular pathway defining long term potentiation (LTP) shows that profiles are 
consistent with both abnormal LTP in vehicle-treated Ts65Dn and its observed rescue by 
RO4938581. Lastly, comparing these results with those from Ts65Dn treated, using a different 
protocol, with the NMDA receptor antagonist, memantine, that also rescues LM impairments, 
identifies common and divergent responses to the two drugs. Expansion of this approach to 
include additional drugs and DS models would aid in determining critical protein abnormalities 
and in identifying cocktails of drugs and/or new drug targets that would be effective in clinical 
trials for ID in DS. 
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Introduction 
 Down syndrome (DS), also known as trisomy 21, is caused by an extra copy of all or, 
rarely, part of human chromosome 21 (Hsa21). The phenotype of DS is variable among 
individuals in the extent of organ systems affected and in severity (reviewed in Karmaloff-Smith 
et al.. 2016), but common to all individuals is some level of intellectual disability (ID) (Chapman 
and Hesketh 2000; Silverman 2007). With a worldwide incidence of approximately one in 700-
1000 live births, DS is the most common genetic cause of ID (CDC 2006; Irving et al.. 2008; 
Parker et al. 2010). Because the life expectancy is now ~60 years, people with DS represent an 
increasingly significant proportion of the population (Irving et al. 2008; Glasson et al. 2002; 
Bittles and Glasson 2004; Bittles et al. 2007; Kucik et al. 2013; Glasson et al. 2016; de Graaf et 
al. 2016). There are, however, no pharmacological treatments for the cognitive deficits.  
 DS is not simple to model in mouse because orthologs of Hsa21 protein coding genes 
map to three mouse chromosomes, Mmu16, 17 and 10 (Davisson et al. 1990). Many mouse 
models have been constructed, all partial trisomics (reviewed in Gupta et al. 2016; Choong et al. 
2015; Rueda et al. 2012; Herault et al. 2012; Roubertoux and Carlier 2010). Of these, the oldest 
and most popular is the Ts65Dn that is trisomic for most of the Mmu16 orthologous region, 
encompassing 90 of the ~160 Hsa21 non-keratin associated protein orthologs (Davisson et al. 
1990; Davisson et al. 1993; Reeves et al. 1995; Gupta et al. 2016). The Ts65Dn has been 
extensively analyzed in its >25 year history and has been shown to manifest many features 
similar to those seen in people with DS, including reduced sizes of the hippocampus and 
cerebellum, abnormal neuronal densities and morphologies, and impaired learning and memory 
(LM) in tasks requiring a functional hippocampus (reviewed in Rueda et al. 2012; Roubertoux 
and Carlier 2010). Other phenotypic features of the Ts65Dn include impaired adult neurogenesis 
and abnormalities in electrophysiological properties of long term potentiation (LTP) and long 
term depression (LTD) (Holtzman et al. 1996; Siarey et al. 1997; Kleschevnikov et al. 2004).   
 The Ts65Dn is currently the model used in preclinical evaluations of pharmacotherapies 
for cognition in DS. Over that last several years, >20 drugs, small molecules and nutritional 
supplements have been shown to successfully rescue performance of the Ts65Dn in one or more 
LM tasks (reviewed in Gardiner 2009; Das and Reeves 2011; Gardiner 2014). These drugs are 
diverse in their targets and mechanisms of action. With one exception, they have not been chosen 
because they target an Hsa21-encoded gene product, but rather because they target a downstream 
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cellular or molecular abnormality observed or predicted in the Ts65Dn or the DS brain. 
Examples of such abnormalities, and the drugs that rescue them, include serotonin levels and 
impaired adult neurogenesis rescued by fluoxetine (Clark et al. 2006); repressed LTP associated 
with increased gamma-aminobutyric acid-A-(GABAA)-mediated inhibition rescued by GABAA 
receptor antagonists, pentylenetetrazole and picrotoxin (Fernandez et al. 2007) and α5-GABAA 
negative allosteric modulators (NAMs) RO4938581 and α5IA (Martínez-Cué et al. 2013, 
Braudeau et al.. 2011a); increased N-methyl-D-aspartate (NMDA) receptor activation targeted 
by memantine (Costa et al. 2008); oxidative stress targeted by vitamin E (Busciglio et al. 1995; 
Lockrow et al. 2009; Coskun et al. 2012; Shichiri et al. 2011); and inflammation targeted by 
minocycline (Hunter et al. 2004). Most often, outcome measures for preclinical evaluations in 
the Ts65Dn have involved performance in one or more LM tasks, sometimes measurement of 
LTP and neurogenesis, but rarely molecular assessments. Consequently, little is known about the 
molecular responses that underlie improved LM and, importantly, how diverse drugs can result 
in the common outcome of successful LM. 
 Previously, we reported protein expression in the Ts65Dn after treatment with 
memantine, with and without exposure to LM in context fear conditioning (CFC) (Ahmed et al. 
2014, 2015). Responses were complex, with significant involvement of mitogen-activated-
protein-kinase (MAPK) and mechanistic-target-of-rapamycin (MTOR) pathways, as well as 
ionotropic glutamate receptor subunits and interacting proteins. To distinguish abnormalities that 
contribute to LM impairment from those that compensate for the initial trisomy-induced 
abnormalities, and to identify drug responses critical to rescue of LM impairment, it is necessary 
to examine effects of additional drugs. 
 Increased GABAA-mediated inhibition has been proposed to be a crucial mechanism 
contributing to the LM alterations found in the Ts65Dn mouse. This has motivated the testing of 
several compounds for reduction of inhibition (Fernandez et al. 2007; Braudeau et al. 2011 a, b; 
Martinez-Cué et al. 2013). RO4938581 (3-bromo-10-(difluoromethyl)-9H-benzo[f]imidazo[1,5-
a][1,2,4]triazolo[1,5-d][1,4]diazepine) is a GABAA receptor NAM, with dual binding and 
functional affinity specific for GABAA receptors containing the α5 subunit (Ballard et al. 2009). 
Chronic oral administration of RO4938581 to Ts65Dn mice has been shown to improve LM and 
to rescue LTP and neurogenesis, without the side effects, such as anxiety and convulsions, seen 
with non-selective GABAA receptor modulators (Martinez-Cué et al. 2013). No Hsa21 encoded 
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genes are known to affect GABAA receptor function or signaling, and the molecular mechanisms 
underlying the functional and morphological rescue of Ts65Dn phenotypes by this NAM have 
not been investigated. Here, we report analysis of Ts65Dn hippocampal protein expression after 
treatment with the GABAAα5 NAM, RO4938581. 
 
Experimental procedures 
Mice 
 Brain tissue was obtained from two sets of male mice. Set 1 included 4-5 mice per 
genotype-treatment group (Ts65Dn and euploid controls, treated with vehicle and drug) from 
those previously reported by Martínez-Cué et al. 2013. Set 2 included an additional 5-7 mice per 
genotype-treatment group subjected to a similar protocol as Set 1. In both Set 1 and Set 2, male 
Ts65Dn and littermate controls, at 3-4 months of age, were given either chocolate milk (Puleva, 
Spain) alone (vehicle) or chocolate milk containing the GABAAα5 NAM, RO4938581 
(Hoffman-La Roche, Basel, Switzerland; 20 mg/kg). Under the conditions used here, 
RO4938581 crosses the blood-brain barrier, based on our observation that, in both euploid 
controls and Ts65Dn, 20 mg/kg RO4938581 decreased specific binding of [3H]RO0154513 (an 
analog which has high affinity for the GABAAα5 subunit) in hippocampus by 68% and 72%, 
respectively (Martinez-Cué et al 2013). The dose of 20 mg/kg RO4938581 in 150 µl was chosen 
because it led to plasma concentrations that correlated with 50– 70% GABAA α5 receptor 
occupancy (Martinez-Cué et al. 2013). 
 Prior to the start of experiments, Ts65Dn and euploid control mice were conditioned to 
drink chocolate milk: each day, for one week, mice were individually placed in a clean standard 
cage containing a small Petrie dish with 150 µl of chocolate milk. After drinking the milk, mice 
were returned to their home cage; all mice drank all the chocolate milk within 5 minutes. During 
the next 6 weeks, every day at 10:00 AM, mice were again placed into a clean cage now with 
either milk alone or milk plus RO4938581 and returned to their home cage after drinking. During 
the subsequent 6 weeks, the drug/milk protocol continued while mice were exposed to behavioral 
assessments. All mice consistently consumed the entire chocolate milk–drug mixture.  
 
Behavioral assessments 
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 The battery of behavioral and LM tasks, included in order: actimetry, reflex test battery, 
rotarod, open field, elevated plus maze, hole board, and the Morris water maze (MWM) as 
described in detail in Martínez-Cué et al. (2013). Briefly, the spontaneous activity test measured 
the animal’s locomotor activity during a complete light/dark cycle of 24 h. In this test, the Acti-
System II (Panlab) apparatus measures the changes in a magnetic field produced by the animal’s 
movement. In the visual placing reflex test, cerebellar and vestibular functions were evaluated. 
To evaluate auditory sensitivity, the startle response to a sudden auditory stimulus was measured. 
To evaluate equilibrium, four 20 s trials of balance were performed on a 40 cm high, 50 cm long 
horizontal rod. Trials 1 and 2 were performed on a 9 mm wide flat wooden rod; trials 3 and 4 
used a 1 cm diameter cylindrical aluminum rod. Prehensile reflex (three 5 s trials) was measured 
as the ability of the animal to remain suspended by the forepaws by grasping an elevated 2 mm 
diameter horizontal wire. Motor coordination was evaluated on a 37 cm long, 3 cm diameter 
plastic rod that rotated at different speeds (Ugo Basile). In a single session, four trials with a 
maximum duration of 60 s each were performed. In the first three sessions, the rod rotated at 
constant speeds of 5, 25, and 50 rpm, respectively. In the last trial, the rod rotated progressively 
faster. The length of time that each animal stayed on the rotarod during the acceleration cycle 
was recorded. The modified version of the Morris Water Maze, used to evaluate spatial learning 
and memory, was described in Martínez-Cué et al. (2013). Briefly, mice were exposed to 16 
consecutive daily sessions: 12 acquisition sessions (platform submerged 1 cm), followed by a 
probe trial and four cued sessions (platform visible). During the first eight sessions, the platform 
quadrant location was changed every day to assess spatial working memory. In sessions 9–12, 
the platform was placed in the SW quadrant (standard protocol) to assess spatial learning. Set 1 
mice were administered the drug or vehicle 60 minutes before the start of each session; 24 hours 
after session 12, mice were exposed to a probe test. Set 2 mice received the drug or vehicle 60 
minutes before each of sessions 1-8, but 60 minutes after each of sessions 9-12; Set 2 mice were 
not subjected to a probe trial. Set 2 mice were studied after publication of Set 1 mice (Martinez-
Cué et al. (2013). The change in timing of drug treatment in sessions 9-12 was used to determine 
if the LM improvement seen in the MWM persisted when the drug was no longer present in the 
receptor (RO4938581 has an elimination half-life of one hour).  However, because proteomic 
analysis was to be carried out on both sets of mice, it was important that all mice receive the 
same daily dose of drug/milk. Therefore, to be consistent with Set 1 mice in daily dose of 
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milk/drug, Set 2 mice instead received the drug/milk 60 minutes after MWM exposure. There 
were no statistically significant differences between Set 1and Set 2 mice in performance of any 
task. MWM performance for the two sets of mice are shown in Figure 1(complete data available 
from the authors). 
 After completion of testing, both Set 1 and Set 2 mice were sacrificed by cervical 
dislocation without anesthetic 60 minutes after treatment with drug or vehicle; the hippocampus 
was rapidly dissected out, flash frozen in liquid nitrogen, and shipped on dry ice to the 
University of Colorado Denver. Information for each mouse on age and littermates is provided in 
Appendix A (available from the authors). For analysis of protein expression, data from mice 
from corresponding genotype/treatment groups from Set 1 and Set 2 were pooled, resulting in 
10-12 individuals per group. Because there were slight differences between Set 1 and Set 2 mice 
in the timing of drug administration during the last sessions of the MWM, pooling was used to 
identify protein responses that are common to both Set 1 and Set 2 mice. Mice used in protein 
expression data obtained from Ts65Dn and euploid controls exposed to context fear conditioning 
with and without treatment with the NMDAR open channel blocker, memantine, have been 
described (Ahmed et al. 2014, 2015). 
 
Protein lysates and reverse phase protein arrays 
 Procedures for preparation of hippocampal lysates and printing and screening of reverse 
phase protein arrays (RPPA) were as described (Ahmed et al. 2011, 2012, 2013). Briefly, to 
optimally preserve protein profiles, tissues were removed from the freezer and, without thawing, 
heat stabilized in the Stabilizor T1 (Denator, AB), as previously described (Ahmed and Gardiner 
2011; Ahmed et al 2012). Protein lysates from individual hippocampal samples were prepared by 
standard protocols in isoelectric focusing (IEF) buffer [8 M urea, 4% 3-[(3-cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS), 50 mM Tris]. Protein concentrations for all 
samples, measured by the 660 nM Protein Assay kit (Pierce), were within the range of 9-11 
mg/ml. Samples were printed, in triplicates of a five point dilution series, onto nitrocellulose-
coated glass slides (Grace Bio-Laboratories, Inc., Bend, OR) using an Aushon BioSystems 2470 
Arrayer (Aushon BioSystems, Billerica, MA). The arrays were produced in two print runs and 
slides were stored at 4oC until use.  
  
9 
 
 For antibody screening of arrays, slides were incubated in blocking solution, followed by 
primary and secondary antibodies using protocols similar to those for Western blots as described 
in Ahmed et al 2012. Bound primary antibodies were detected using Alexa Fluor 555 goat anti-
mouse or anti-rabbit or rabbit anti-goat (Invitrogen, Camarillo, CA, USA). To control for 
variation in protein concentration between spots, total protein in each spot was assessed by 
staining three non-sequential slides from each print run with the general protein stain SyproRuby 
following the manufacturer’s directions. For use in all analyses, antibody signal was normalized 
to the corresponding SyproRuby signal. Details of quantification, review of data quality and 
reproducibility were as described previously (Ahmed et al 2012; see also 
http://downsyndrome.ucdenver.edu/iddrc/rppaware/home.htm). RPPA is a high throughput dot 
blot procedure. It has been extensively validated for accuracy and reproducibility in our own 
work (Ahmed et al 2012) and in that of others (Espina et al 2007; Pierobon et al 2011). Indeed, 
its reliability has supported its use in clinical trials for cancer prediction and prognosis (reviewed 
in Pierobon et al 2015). Small sample volumes precluded use of Western blots. A list of all 
antibodies and files containing SyproRuby and all antibody raw signal intensities are provided in 
Appendix B (available from the authors). 
 
Statistics 
 Each genotype-treatment group was composed of a total of 10-12 mice, 4-7 each from 
Set 1 and Set 2. Data from individual mice in Set 1 and Set 2 in the corresponding groups were 
pooled, (i) because behavioral performances did not differ significantly between Set 1 and Set 2 
corresponding genotype/treatment groups and (ii) in order to identify protein responses that were 
common to the corresponding groups in the two sets. Each SyproRuby normalized protein value 
was included in the statistical analysis if the level was within +/-10% of the mean of the 15 spots 
for that sample. Samples with fewer than 7 normalized protein values within 10% of the mean 
for a specific antibody were eliminated from calculations for that antibody; fewer than 5% of 
sample measurements were removed. Mean differences between genotypes of each treatment 
(trisomy vs. control, reported as % of control) and between treatments (drug vs. vehicle) for each 
genotype were assessed using a hierarchical three-level mixed effects model (3LME). 3LME is 
commonly used in cases where multiple measurements are made on the same subject which can 
give rise to erroneous significance in relationships between groups 
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(www.stat.cmu.edu/~hseltman/309/Book/chapter15.pdf). 3LME is appropriate here because for 
each protein, each sample was printed in three replicates of a 5 point dilution series, i.e. 15 
measurements per sample. Mixed models contain both random and fixed effects; the mouse is 
the fixed effect, and replicates and dilutions are the random effects. The Benjamini-Hochberg 
corrected p-value < 0.05 with a false discovery rate (FDR) of 5% was considered for overall 
statistical significance across the entirety of the hypotheses. Results of all comparisons are 
provided in Appendix C (available from the authors).  
 Correlations among protein levels were determined by standard Spearman correlation 
analysis, with cutoffs for significance: correlation coefficient, r>|0.80| and p<0.05. This test was 
chosen to assess the monotonic relationship between levels of two different proteins within the 
same set of mice; specifically here, it assesses the relationship between the levels of two different 
proteins within individuals in a single genotype-treatment group. If levels of two proteins are 
correlated, then as the levels of one protein increase when levels in individual mice are listed in 
rank order, the levels of the second protein also increase, or decrease (positive and negative 
correlations, respectively) in the same mice. An artefactually high r value can be generated when 
a protein dataset for a genotype-treatment group contains outliers or subgroups, or when low 
numbers of mice are associated with quality protein measurements. Scatter plots of all significant 
pairwise comparisons were manually reviewed and those with artefactually high r values were 
eliminated. Examples are provided in Figure 4. 
 
Results 
 Proteins were measured in hippocampus from four groups of mice: two genotypes, 
trisomic Ts65Dn and euploid controls, and two treatments, vehicle and the GABAAα5 NAM, 
RO4938581. As described in Martinez-Cué et al. (2013), treatments were chronic, administered 
daily starting at 3-4 months of age, for 6 weeks before, and subsequently during, a behavior and 
learning/memory (LM) test battery that spanned a further 6 weeks. Protein profiles were thus 
generated from 6-7 month old mice and expression patterns reflect the combined effects of 
genotype, long term drug exposure and the stimulation and stress of the test battery. Groups are 
designated based on their performance in the MWM. In comparison with euploid controls, 
Ts65Dn treated with vehicle show impaired performance in the MWM and are designated as 
failed (F). Ts65Dn mice treated with RO4938581 show significantly improved performance 
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(although not to levels of controls) and are designated as partially rescued (R). Euploid control 
mice learn equally well with vehicle and RO4938581, and are considered to show normal 
learning (designated as N and NR, respectively). Protein expression analysis focused on 
between-group comparisons. While six pairwise comparisons are possible, four were of 
biological interest and are listed in Table 1. 
 Levels of 91 proteins were measured in the hippocampal samples. Twenty-seven 
measurements were to phosphorylation-specific, two were to acetylation-specific and the 
remainder were to modification-independent protein forms. A list of all the proteins can be found 
in Appendix B (available from the authors). 
 
General features of the protein profiles 
 Table 2 summarizes, for each comparison, the number of proteins that differed between 
the two groups and the relative magnitudes of the differences. Two comparisons standout for the 
extent of the differences: FvN and RvF have 52 and 57 differences, respectively, compared to 
only 10 and 13 for RvN and NRvN. The magnitudes of the differences were also proportionately 
greater in FvN and RvF. In FvN, 30 of 52 differences were >20% (24 were increases and 6 were 
decreases) and in RvF, 37 of 57 differences were >20% (8 increases and 29 decreases). This is in 
contrast to only 4 of 10 and 2 of 13 differences >20% in RvN and NRvN.  
 Table 3 summarizes the number of proteins showing abnormal levels within six 
functional classes. The MAPK and MTOR pathways are well established for roles in LM and 
show many abnormalities in FvN and many responses to RO4938581 in RvF. In contrast, 
however, and consistent with improved and normal LM, respectively, there are many fewer 
differences in MAPK and MTOR components in RvN and NRvN. Also showing many trisomic 
perturbations and responses to RO4938581 are proteins related to NMDAR subunits and 
interactions, and AD-related proteins. Again, there are few differences in levels of these proteins 
in mice with improved and normal learning. Smaller numbers of immediate early gene (IEG) and 
apoptosis proteins were measured but these also show abnormalities in FvN that are normalized 
in response to successful learning (e.g. RvN).  
 Together, the data in Tables 2 and 3 indicate extensive abnormalities in protein 
expression in the Ts65Dn when they fail the MWM (FvN) and extensive responses to 
RO4938581 in the Ts65Dn when they then learn better in the MWM (RvF). Some of the former 
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responses may contribute to the LM failure, while some of the latter may contribute to the 
associated rescue of LM. Consistent with this, when the Ts65Dn learn better, the differences 
from controls in protein expression are reduced (RvN). RO4938581, however, is not without 
effects in control mice on components of MAPK and MTOR pathways, and NMDAR related 
proteins. Indeed, there are more differences in NRvN than in RvN. However, because NR mice 
learn normally, these differences either are not relevant to LM, are compensated by other 
changes, or the experimental protocol used to assess LM (MWM) was not able to detect subtle 
improvements in cognition in RO4938581 treated control mice.  
 The Venn diagram in Figure 2 illustrates common protein features among the four 
comparisons. Of the 91 proteins measured, only 23 did not differ in any comparison. Most 
notably, 44 proteins were affected in both FvN and RvF comparisons, and in all cases, the 
differences were opposite in direction. This indicates that RO4938581 tends to normalize levels 
of the proteins that are elevated or decreased in the Ts65Dn.  
 
Hsa21 proteins 
 Due to dosage, trisomy is expected to lead to a 50% increase in expression levels of 
trisomic genes. As shown in Figure 3A, in the FvN comparison, this is indeed true: protein levels 
of trisomic genes APP, ITSN1, and RCAN1 are ~60% higher than controls, and those of 
DONSON, DYRK1A, SOD1, and TIAM1 are elevated by 20%-30%. Exceptions exist, however: 
the level of ETS2, that is trisomic, and the level of PRMT2, that is not trisomic (it maps to 
Mmu10), are both decreased by ~10%. There is no difference from controls in ADARB1 and 
RRP1 protein levels; these genes also map to Mmu10 and are not trisomic in the TS65Dn. The 
effects of RO4938581 on the Hsa21 orthologs are shown in Figures 3B and C. Unexpectedly, 
because the molecular mechanism relating a GABA receptor modulator to expression of these 
genes is completely unclear, levels of these proteins are largely normalized: decreased in the RvF 
comparison sufficiently that, with the exception of APP and SOD1, levels are not different from 
controls in RvN. Even the magnitude of the APP abnormality is reduced, from ~60% to only 
10% greater than controls with RO4938581 treatment. However, in control mice, RO4938581 
has no consequences for these same Hsa21 orthologs (Figure 3D). 
  
NMDA Receptors and Related Proteins 
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 Figure 3E-H shows a similar analysis of subunits of ionotropic glutamate receptors and 
functionally related proteins. As shown in Figure 3E, the NMDA receptor (NMDAR) subunits, 
NR1, NR2A, and NR2B, and their phosphorylated forms are repressed by ~20% in FvN. 
Subunits of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor are 
also decreased, as is the level of BDNF, a neurotrophic factor with a crucial role in neurogenesis. 
Only TRKA is elevated. Drug treatment reverses most of these abnormalities (Figure 3F) so that 
in RvN there are no significant differences in levels of any of these proteins. RO4938581 does, 
however, have some effects in control mice, increasing levels of pNR1, pNR2B and GLUR3. 
  
Signaling pathways  
 Table 4 lists differences in MAPK and MTOR pathway components. Comparing columns 
1 and 3 shows that RO4938581 normalizes most of the abnormalities seen in mice with impaired 
learning and residual differences tend to be small. Exceptions include, in both Ts65Dn and 
control mice treated with RO4938581, decreased levels of BRAF (-14% and -16%) and pERK (-
24% and -23%) in RvN and NRvN. Specific to RvN is a decreased level of pAKT (-27%) and to 
NRvN, a decreased level of pS6 (-20%). Table 5 shows results of the same comparisons for IEG 
and AD-related proteins. RO4938581 normalizes the levels of CFOS and pCFOS, as well as 
levels of pTAU, pSRC and CHAT. Conversely, RO4938581 creates abnormalities in levels of 
ERBB4, decreasing levels by 14%-26%, in both Ts65Dn and controls. Also of interest are the 
responses to RO4938581 of the histone H3 modifications; specific to the Ts65Dn are decreases 
in levels of acetylation of H3 lysines 18 and 9. 
 
Correlations among protein levels 
 The Ts65Dn are maintained by mating trisomic females to C57BL/6JEi x C3H/HeSnJ F1 
hybrid males (Davisson et al.. 1990, 1993). At any locus therefore, euploid and trisomic 
individuals will have 0, 1 or 2 alleles from C57BL/6JEi and C3H/HeSnJ. The resulting sequence 
variation, depending on genomic location, can cause within-genotype, inter-individual variation 
in gene expression at the mRNA and protein levels. This has been reported previously at the 
protein level in naïve Ts65Dn where it was used to generate networks of correlated levels of 
functionally related proteins (Ahmed et al. 2012). To investigate possible consequences of 
genomic sequence variation in the current sets of mice, we carried out standard Spearman 
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correlation analysis for all pairs of proteins in euploid and trisomic mice, separately for vehicle 
and R04938581 treated groups.  
 Measurement of 91 proteins/protein modifications results in (91 X 90) ÷ 2, or ~4100, 
pairwise comparisons for each of the four genotype/treatment groups, for a total of ~16,000 
comparisons. We retained as significant those with correlation coefficient r >|0.80| and p<0.05. 
For all significant correlations, scatter plots were reviewed for the presence of monotonic 
relationships between protein levels. Figures 4A-D show the relationships between levels of 
pNR1 and pNR2B. In 3 of 4 genotype/treatment comparisons, levels of both proteins increase 
monotonically. Strong correlations are present in both euploid controls and Ts65Dn treated with 
vehicle (Figure 4A,B). The correlation remains in drug treated Ts65Dn (Figure 4C, r=0.87, 
p=0.004), but is lost in RO4938581 treated controls (Figure 4D, r=0.45, p=0.24). Scatter plots in 
Figures 4E,F illustrate the strong correlations, in drug treated mice, between GAD2 and PP2A. In 
contrast, scatter plots in Figure 4G and H illustrate correlations that meet the numerical criteria 
but that were eliminated because of potential artifacts. In Figure 4G, while the r value is high 
(r=0.96), the data in vehicle treated controls appear in two clusters, suggesting the possibility of 
two groups of mice, one with low values of both DYRK1A and RCAN1 and the other with high 
values of both proteins. In Figure 4H, the relationship between pNR2A and CFOS in vehicle 
treated Ts65Dn is ambiguous; while the r value is high, there are again possibly different groups 
of mice, one group where pNR2A levels increase while CFOS levels are relatively constant and 
one where pNR2A levels remain constant while CFOS levels increase. Increasing the number of 
individuals in each group would resolve the kinds of ambiguities seen in Figures 4G,H. For 
purposes here, however, we used stringent criteria and retained only those correlations showing 
no potential artefacts. 
  Within each treatment group, correlations included some that were specific to either 
euploid controls or Ts65Dn and some that were common to both genotypes. After manual review 
of scatter plots and elimination of those with artefactual significance (see Methods), two features 
of the final set of correlations were evident. First, in vehicle-treated mice, the Ts65Dn frequently 
have much larger numbers of correlated proteins than do euploid controls. For example, as 
shown in Table 6, in the Ts65Dn, CFOS and pGLUR2 are correlated with 18 and 19 proteins, 
respectively, while in euploid controls they are correlated with only 4 proteins each (total 
correlations for a genotype-treatment are the sum of the number of correlations common to both 
  
15 
 
genotypes plus the number of correlations that are genotype specific). Second, for most proteins, 
many correlations seen in vehicle treated Ts65Dn mice, including both those in common with 
controls and those specific to Ts65Dn, are lost in R04938581 treated mice, while few new 
correlations appear. For example, CFOS correlations are reduced from 18 to 2 in Ts65Dn and 
those for pGLUR2 are reduced from 19 to 7 (Table 6).  
 Patterns of correlations among proteins can be illustrated as networks. Examples for 
selected proteins are shown in Figures 5 and 6 (although some proteins are present in both 
figures, the networks are shown separately for clarity). Figure 5 illustrates networks involving 
subunits of ionotropic glutamate receptors. For each of three NMDAR subunits, NR1, NR2A and 
NR2B, one phosphorylation-independent and one phosphorylation-dependent form were 
measured. Figure 5A shows that, in vehicle treated mice, levels of five of these forms are 
correlated in 8 pairwise comparisons that are common to both euploid controls and Ts65Dn. Of 
the three AMPAR subunits measured, uniquely in the Ts65Dn, levels of pGLUR2 are correlated 
with each of the five NMDAR subunits, while correlated only with GLUR4 in euploid controls. 
Figures 5B,C show the networks in RO4938581 treated mice. Of the correlations among 
NMDAR subunits, only 2 remain in euploid mice, between pNR1 and NR2A and NR2B. 
Conversely, in Ts65Dn, 7 of 8 common correlations remain, with only that between NR1 and 
pNR1 lost. Unique to the Ts65Dn is the number of correlations between NMDAR and GLUR4 
and BDNF. Additional correlations involve GAD2 (glutamic acid decarboxylase), of interest 
because it catalyzes the production of gamma-aminobutyric acid from L-glutamic acid. Common 
to both genotypes are new correlations between GAD2 and pGLUR2 and GLUR4, and between 
pGLUR2 and GLUR3.  
 Networks involving the serine-threonine protein phosphatase, PP2A, PPP2R1A subunit, 
are shown in Figure 6. PP2A functions in regulation of MAPK and AKT signaling and among its 
targets are Tau, GSK3B and DYRK1A. PP2A, and its networks, are among the minority of 
proteins where the number of correlations common to euploid and Ts65Dn increases, rather than 
decreases, with drug treatment. In vehicle treated mice (Figure 6A), there are common 
correlations involving 4 proteins, 3 of which are between PP2A and pGLUR2, GFAP and RSK. 
In drug treated mice (Figure 6B), the network is much more dense; there are 13 common 
correlations, involving 7 proteins; 6 correlations involve PP2A. Some of these new common 
correlations were genotype-specific in vehicle treated mice, however, the Ts65Dn-specific 
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correlations seen in vehicle treated mice involving NMDAR subunits, DYRK1A and ARC are 
lost. Drug induced correlations again include GAD2, and those with PP2A and RSK are common 
to both genotypes. 
 
Discussion 
 Levels of 91 proteins/protein modifications were measured in hippocampus of Ts65Dn 
and littermate control mice after exposure to a battery of behavioral and LM tests, with and 
without chronic treatment with the GABAAα5 NAM, RO4938581. The diversity of proteins 
measured reveals the complexity in the Ts65Dn of both the initial perturbations and the 
responses to the drug, and the relationships between these data sets. Most notably, of the 52 
proteins showing abnormal levels in the vehicle treated Ts65Dn, 44 responded to RO4938581 
with direction and magnitudes of changes that largely tended to normalize these protein levels. 
These proteins include several encoded by Hsa21, levels and activation of components of the 
MAPK and MTOR pathways, IEG proteins, subunits of ionotropic glutamate receptors and AD-
related proteins. While each of these pathways and processes has well established relevance to 
LM, the direct molecular mechanisms relating their responses to GABAA signaling, and its 
inhibition, and to the functions of Hsa21 genes, are not known and normalization of such a broad 
range of proteins was unexpected.  
 RO4938581 binds directly to the α5 subunit of the GABAA receptor. No transcription 
factors, and indeed no other proteins, are known to be targets. However, RO4938581 treatment 
may indirectly result in changes in transcription or protein post translational modifications, first 
because RO4938581 binding is known to reduce inhibition. The associated increase in excitatory 
neurotransmission will result in activity-dependent plasticity which activates transcription of 
many genes (Flavell and Greenberg, 2008). In addition, because GABAA α5 receptors are 
localized at dendrites of pyramidal cells in close proximity to NMDA receptors, inhibition of 
GABAA receptor activity may contribute to activation of NMDA receptors, with consequent 
downstream responses in signaling pathways.  
 Measurement of mRNA levels, by qPCR, microarrays or sequencing, in Ts65Dn with and 
without drug treatment, would determine if RO4938581 represses transcription of the trisomic 
genes APP, SOD1, ITSN1, DYRK1A and RCAN1. Each of these Hsa21 orthologs is well 
established to contribute to the trisomy phenotype in mouse models of DS and each is commonly 
  
17 
 
found to be elevated in tissues from DS and mouse models (Vilardell et al 2011). If 
normalization of mRNA levels underlies the observed normalization of protein levels found here, 
further studies would be needed to determine the mechanisms of such regulation, i.e. is direct 
repression of trisomic gene transcription caused by altered levels or activation of necessary 
transcription factors, or more indirectly, are mRNA levels reduced due to increased rates of 
degradation? However, mRNA levels do not reliably predict protein levels (Schwanhausser et al. 
2011; Vogel and Marcotte 2011). Therefore, normalization of protein levels does not require 
RO4938581 to influence transcription. Alternatively, it may negatively affect efficiency of 
translation or protein stability.  
 In the prior Ts65Dn report, Martinez-Cué et al (2013) showed that RO4938581 treatment 
rescued multiple abnormalities in synaptic plasticity and cellular features that have been well 
established in untreated Ts65Dn (Insausti et al., 1998; Rueda et al., 2005; Clark et al., 2006; 
Lorenzi and Reeves, 2006; Bianchi et al., 2010; Llorens-Martín et al., 2010). This included 
rescue of deficits in adult neuronal proliferation and survival, and normalization of LTP. GABAA 
receptor activity has been shown to regulate neuronal proliferation, migration, differentiation, 
and integration of newly generated neurons (Tozuka et al., 2005; Ge et al., 2006; Earnheart et al., 
2007; Song et al., 2012). Because both newborn and mature neurons are implicated in 
hippocampus dependent learning and memory, the restoration of proliferation and the density of 
mature neurons is likely to be involved in the cognitive-enhancing effects of RO4938581 in TS 
mice. Furthermore, the correction by RO4938581 treatment of abnormal expression of glutamate 
receptors subunits may also contribute to reducing the over-inhibition and hence rescuing LTP.  
 
Comparison with prior Ts65Dn expression studies 
 Braudeau et al. (2011a) measured responses by microarrays and qPCR to treatment with 
the partial inverse agonist, 3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2, 3-triazol-4-
yl)methyloxy]-1, 2, 4-triazolo[3, 4-a]phthalazine (α5IA). In hippocampus of vehicle treated 
Ts65Dn mice, levels of ITSN1 and SOD1 were elevated, consistent with protein results here. In 
contrast, levels of APP, TIAM1, RCAN1 or DYRK1A did not differ from euploids, while here 
each was significantly elevated at the protein level. α5IA rescued the Ts65Dn impairments in 
learning in the MWM and also normalized SOD1 mRNA levels; this normalization did not occur 
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at the protein level with RO4938581. That mRNA levels do not reliably predict protein levels 
(Schwanhausser et al. 2011; Vogel and Marcotte 2012) may account for these disparate results. 
 For non-Hsa21 orthologs, Braudeau et al. (2011a) reported significantly reduced CFOS in 
hippocampus of vehicle treated Ts65Dn relative to controls, and normalization of these levels 
after treatment with α5IA; similar increases in CFOS were also seen in controls. At the protein 
level, Braudeau et al. (2011b) measured CFOS immunostaining in the dentate gyrus and CA1 
region of the hippocampus after acquisition in the NOR. Levels did not differ between vehicle 
treated Ts65Dn and controls, in contrast to the authors’ mRNA data (Braudeau et al. 2011a), nor 
between α5IA treated Ts65Dn and controls. Again, these results partially agree with those found 
here: the CFOS protein level was reduced relative to controls in Ts65Dn vehicle treated mice, 
and RO4938581 treatment normalized the CFOS level, without affecting that in controls. 
 At least some of the differences in results likely reflect differences in experimental 
paradigms. Here, mice were subjected to a battery of behavioral and LM tests, and administered 
RO4938581 for 6 weeks prior to, and for an additional 6 weeks during, testing. In contrast, in 
Braudeau et al. (2011a,b), mice were exposed only to a single test, either the MWM or NOR, and 
were treated with α5IA for shorter periods of time, in the NOR experiments, with a single dose 
(Braudeau et al. 2011b). Differences in the amount of handling, and the stress and stimulation 
associated with a series of evaluations, versus a single one, may also contribute to gene 
expression differences. This is well illustrated by considering results from a comprehensive 
analysis of protein expression in naïve Ts65Dn mice reported in Ahmed et al (2012). Vehicle 
treated Ts65Dn mice here show a very different profile of abnormalities from those seen in 
Ahmed et al (2012). These affect both Hsa21 orthologs, e.g. TIAM1, that was not elevated in 
hippocampus of naïve Ts65Dn, and non-Hsa21 orthologs (data not shown). A thorough 
exploration of these differences should help to understand the molecular basis of Ts65Dn 
impairments and will be reported in the future. 
 
Correlation networks  
 Protein correlations present a novel view of molecular events in LM and drug responses. 
The biological significance, however, of correlations and their associated networks, remains to 
be determined and there is evidence both for and against it. Support for biological relevance is 
the observation of correlated levels among proteins known to form a functional complex. In such 
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cases, correlated levels might reflect the need to maintain specific levels of each component to 
correctly assemble and regulate the activity of the complex. One example, in vehicle treated 
euploid mice, involves the highly correlated levels of NMDAR subunits, where 5 of the 6 
proteins are present in a network of 8 pairs (Figure 3A). On the other hand, in RO4938581 
treated euploid mice, 6 of these correlations are lost. Euploid mice perform and learn the sets of 
tasks equally well with and without the drug. This argues against the biological relevance, for the 
behaviors and tasks examined here, of the specific correlations among NMDAR subunits. 
 Interpretation of the biological relevance is further complicated by observations in 
Ts65Dn. Correlations among NMDAR subunits in vehicle treated Ts65Dn are similar to those in 
euploid mice. This differs from results of a prior analysis of naïve mice, where Ts65Dn had 
many fewer correlations than euploid littermates among these same proteins (Ahmed et al. 
2012). In that work, it was argued that the absence of correlated levels in trisomy might 
contribute to neurological abnormalities. The age of mice in Ahmed et al. (2012) was similar to 
that of mice here. It is possible, therefore, that the stimulation of daily exposure to handling, 
novelty and the MWM experienced by the mice here, induces changes in relative protein levels 
to result in correlated values. That the vehicle treated Ts65Dn network appears similar to 
euploids suggests that some normal responses occur with the stimulation to learn, in spite of the 
impairment in performance. In drug treated Ts65Dn mice, the majority of correlations among 
NMDAR subunits remain, in contrast to their loss in drug treated euploid mice. The presence and 
persistence of correlations between NMDAR subunits and BDNF and AMPA subunits uniquely 
in the Ts65Dn needs to be explored for relevance to molecular mechanisms that may contribute 
to or compensate for abnormal responses to stimulation.   
 Correlations do not necessarily reflect known physical associations. This is illustrated in 
PP2A-PPP2R1A subunit networks. The PP2A protein phosphatase is a multi-subunit complex, 
composed of catalytic, regulatory and scaffolding subunits. There are multiple genes encoding 
each type of subunit, leading to considerable diversity in PP2A holoenzyme composition, and 
consequent diversity in activity level and substrate specificities and affinities (reviewed in 
Nematullah et al. 2017; Kiely and Kiely 2015). Because only the regulatory subunit PPP2R1A 
was measured here, only a partial view of PP2A relationships is generated. To interpret the PP2A 
network, we considered both protein interaction partners and substrates. Of >300 interaction 
partners identified for PPP2R1A (NCBI Gene #2538), NR1 and AKT were measured here, and 
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of known substrates, DYRK1A, TAU, AKT and MAPK components were measured. Of these, 
NR1 (only the phosphorylated form) and DYRK1A levels were correlated with PP2A in the 
vehicle treated, but not drug treated, Ts65Dn, and the MAPK component RSK was correlated in 
both genotypes and treatments. That the PP2A networks involve a number of other proteins, 
therefore, may indicate novel interaction partners, substrates of the PPP2R1A subunit, unknown 
indirect functional relationships, or merely curious artefacts. 
 An additional network feature, after RO4938581 treatment, is the appearance of GAD2 in 
common and genotype specific correlations. These novel correlations may be explained by the 
target and mechanism of action of RO4938581. RO4958381 binds to the GABAAα5 subunit and 
negatively modulates activity of the receptor. The majority of GABAAα5 receptors are localized 
extrasynaptically and mediate tonic inhibition in response to extracellular ambient GABA 
(Serwanski et al. 2006). It has been suggested that changes in the activity of synaptic and 
extrasynaptic GABAA receptors might impact GAD2 activity, thus, indirectly influencing GABA 
synthesis and release (Blednov et al. 2010). GABAergic activity is elevated in the vehicle treated 
Ts65Dn (Martinez-Cué et al. 2013), and the level of GAD2, which regulates GABA synthesis, is 
repressed, a reasonable compensatory response to over inhibition. In these conditions, GAD2 
levels are not correlated with any proteins. Because GABAergic synapses adjust their strength 
depending on the pattern of neuronal activity (Melle et al. 2016), the RO4938581-induced 
reduction in GABAAα5 receptor activation might be predicted to impact the synthesis of GABA 
by normalizing GAD2 expression. This is indeed observed in the Ts65Dn when inhibition is 
corrected by RO4938581 treatment. This is, however, a genotype-specific correction, because it 
is not observed in euploid controls. The correlations induced by RO4938581 between GAD2 and 
AMPA receptor subunits occur in both genotypes. In the Ts65Dn, additional correlations are 
induced between GAD2 and BDNF, and between GAD2 and phosphorylated forms of NMDAR 
subunits, possibly reflecting mechanisms underlying rescue of the imbalance between excitatory 
and inhibitory neurotransmission that occurs specifically in these mice. Further study is required 
to determine the biological significance and if there exist molecular mechanisms connecting 
GAD2, RO4938581 and components of the correlation networks. 
 No correlations were observed between any parameter of MWM performance and the 
levels of any protein, either in euploid controls or Ts65Dn, in vehicle or drug treated mice. This 
is not surprising given the complexity of learning and memory. It is also consistent with a 
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previous analysis of protein responses in the Ts65Dn subjected to context fear conditioning, with 
and without treatment with the NMDA receptor modulator, memantine (Ahmed et al 2014, 
2015). A more sophisticated bioinformatics approach, using Self-Organizing Feature Maps 
(SOM), was, however, successful in identifying patterns in protein expression that distinguished 
successful learning, in vehicle or drug treated controls and drug treated Ts65Dn, from failed 
learning, in vehicle treated Ts65Dn (Higuera et al. 2015). A similar analysis is in progress with 
data from RO4938581 experiments. 
 
LTP Pathway 
 Long term potentiation is considered to be a cellular mechanism underlying synaptic 
plasticity and LM. Several studies have shown repressed hippocampal LTP in the Ts65Dn 
(Siarey et al. 1997; Kleschevnikov et al. 2004) and treatment with RO4938581 increased LTP in 
Ts65Dn hippocampus to levels not different from untreated controls (Martinez-Cué et al. 2013). 
To gain insight into the molecular basis of this rescue, we superimposed RPPA data onto the 
curated LTP protein pathway from the KEGG database. The pathway was expanded with protein 
interaction partners known to be expressed in brain. Results are shown in Figure 7, with each 
node color-coded for perturbation and response to RO4938581 in the Ts65Dn. Including both 
modification dependent and independent protein forms, a total of 64 proteins, comprising 24 
pathway components and 40 interacting proteins, were measured. Thirteen were unaffected by 
genotype or treatment (shown in grey), and 51 were perturbed in the Ts65Dn (FvN, in yellow), a 
proportion that is consistent with the observation of perturbed LTP. After drug treatment, 
however, there remain only 8 protein abnormalities (RvN, in green): three pathway components, 
CAMKIIα/β, BRAF, and pERK1/2, and five interactors, pAKT, APP, ERBB4 and two histone 
H3 lysine-acetylated forms. This striking decrease in complexity of protein abnormalities is 
consistent with the rescue of repressed LTP, however, this same complexity makes it difficult to 
interpret the molecular mechanisms of RO4938581. The protein abnormalities that are present in 
the vehicle treated Ts65Dn and that are resolved by RO4938581 likely include two types: (i) 
abnormalities that contribute to the LTP defects, or that lie directly downstream of these, and 
respond to RO4938581 inhibition of GABAAα5, and (ii) abnormalities that do not contribute to 
repressed LTP, but rather that were induced as compensation for the trisomic perturbations. The 
latter abnormalities are eliminated by the removal of the initial perturbations. It remains to be 
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determined which proteins belong to each category. This would discriminate those abnormalities 
that are critical to correct from those that, conversely, if removed, would likely exacerbate the 
functional impairment by removing compensatory abnormalities. 
 
The molecular basis of pharmacological rescue of LM after RO4938581 treatment 
 More than 20 drugs, small molecules and nutritional supplements have been shown to 
rescue impaired performance in the Ts65Dn in at least one LM task (reviewed in Gardiner 2009, 
2014; Das and Reeves 2011). Most of these studies used adult mice (Gardiner 2014), suggesting 
that it might be possible to improve cognitive abilities in a large proportion of people with DS, 
i.e. the data suggest that the postnatal, even adult, brain is sufficiently plastic for significant LM 
improvement. A confounding, but interesting, factor is the diversity of targets and mechanisms 
of action of the successful treatments. This fact is often not mentioned in reports of new 
successful treatments nor in limited reviews of the topic (Das et al. 2014), but failing to consider 
it may hamper progress toward effective treatments. Exploiting the diversity of successful drug 
properties to build understanding of the molecular basis of LM rescue could lead to rational 
proposals of new drug targets or creation of a cocktail of drugs that is more effective than any 
single drug. Given the very modest (and negative) results of clinical trials with single drugs 
based on LM evaluations in the Ts65Dn (Boada et al. 2012; Hanney et al. 2012; Lott et al. 2011; 
de la Torre et al. 2016), pursuing new drug targets or cocktails of drugs are reasonable additions 
to proposals of larger trials, longer trials and inclusion of younger participants. 
 In previous work, we examined protein expression changes in response to an NMDAR 
inhibitor, memantine (Ahmed et al. 2015). This allows comparison of the responses to inhibition 
of inhibitory neurotransmission by RO4938581 with those of inhibition of excitatory 
neurotransmission by memantine. There are significant differences in experimental protocols. 
Memantine treatment was acute and mice were exposed to a single task, context fear 
conditioning (CFC) (Ahmed et al. 2015), while RO4938581 treatment was chronic, and mice 
were exposed to multiple behavioral assessments and then the MWM. In addition, memantine 
treated mice were sacrificed 60 minutes after training in CFC. This time point was chosen 
specifically to capture protein responses known to be required for LM in CFC and to occur 
within that time frame, such as MAPK components and IEG proteins (Atkins et al. 1998; Ahmed 
et al. 2014; Ivashkina et al. 2016). In contrast, RO4938581 treated mice were sacrificed 24 hours 
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after the last of several days of training in the MWM. The timing with respect to molecular 
responses required for LM in the MWM is not known, but given the incremental improvements 
in learning seen in sequential training sessions, the time frame is unlikely to be discrete. Protein 
profiles likely also reflect chronic responses to drug treatment, and not specifically LM. Lastly, 
the memantine data were generated from subcellular fractions of the hippocampus (nuclear, 
cytosolic and membrane), while the RO4938581 data were generated from whole hippocampus 
lysates.  
 In Figure 8, we summarize protein expression in the Ts65Dn in two comparisons with 
normal LM in controls: when Ts65Dn fail to learn and when Ts65Dn successfully learn, i.e. the 
FvN and RvN comparisons. In the memantine experiments, the comparisons corresponding to 
FvN and RvN are, respectively, the context-shock (CS)-saline Ts65Dn vs. CS-saline controls and 
the CS-memantine Ts65Dn vs. CS saline controls. Figure 8A shows data for 19 proteins with 
localization to the membrane and the cytosol. These include Hsa21 proteins and NMDAR and 
AMPAR subunits. The FvN comparisons show that the two LM protocols result in different 
profiles of protein perturbations in the Ts65Dn that fail to learn the respective tasks; this is not 
unexpected from the differences in extent, timing and type of LM stimulation. Perturbations in 
vehicle treated Ts65Dn from the RO4938581 experiment show largely repressed levels while 
those from the memantine experiment include elevated levels in both the cytosol and membrane. 
In the RvN data, RO4938581 completely normalizes levels of these proteins, while memantine 
fails to normalize Hsa21 encoded proteins DYRK1A, ITSN1 and TIAM1, as well as elevated 
levels of NR2A and NR2B. In Figure 8B, proteins with cytosolic and nuclear localization are 
shown. The perturbations in the FvN are again quite different between the two LM protocols. 
Those from the battery of tests show 37 abnormalities, largely elevated, while those from only 
CFC show 13 and 11 abnormalities in the nuclear and cytosol fractions, respectively. The RvN 
comparisons in Figure 8B show that RO4938581 results in correction of 32 of the abnormalities 
in impaired LM. Elevated levels of APP or SOD1 remain and there is over compensation in 
levels of BRAF, pERK and STAT3 that now are decreased relative to controls. Memantine 
largely corrected nuclear abnormalities, but was less effective in normalizing cytosolic levels. 
Notably unaffected by memantine were abnormal levels of most of the Hsa21 encoded proteins. 
 Differences in protein profiles likely include some related to the molecular processes 
required for different types of learning, e.g. spatial learning in the MWM vs. associative learning 
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in CFC. It would be useful, however, if they could be used predict impaired performance and 
drug-induced rescue of performance in a range of LM tasks. It is notable that RO4938581 failed 
to correct impairment in CFC (Martinez-Cué, unpublished), while memantine was successful in 
rescue of MWM performance (Rueda et al. 2010). Differences in efficacy in rescue of specific 
LM tasks are not unique to RO4938581; they have been noted in several drug treatments of the 
Ts65Dn, e.g. the GABAB receptor antagonist, CGP55845, rescued performance in object 
recognition, but not in CFC, lithium rescued performance in CFC but not in the T-maze, and the 
Sonic Hedgehog analog, SAG.1. rescued performance in the MWM but in not the Y-maze. 
Comparing protein profiles after each LM task, with and without treatment with individual 
drugs, would help to discriminate normal task-specific responses and those critical to rescue of 
specific Ts65Dn impairments. In this way, protein expression data, could be used to identify 
drugs with efficacy against a broad range of LM tasks or cocktails of drugs, each effective in 
rescuing different tasks. 
 
 This study corroborates extensive abnormalities in protein expression in hippocampus of 
Ts65Dn mice that may contribute to their neurological deficits. Chronic RO4938581 treatment 
rescued most of the molecular abnormalities and many of these deficits. The proteins measured 
included, not only several encoded by Hsa21, but also a broad range of proteins of known 
importance to brain development and function, thus supporting the argument that these 
molecular changes are implicated in the enhanced LM, neurogenesis and LTP found in Ts65Dn 
mice after chronic administration of this NAM. To deconvolute the molecular responses required 
for rescue in the Ts65Dn, additional studies are needed, using consistent LM protocols and 
comparing additional drugs. This is a complicated project and one needing replication in 
additional mouse models of DS, to account for contributions to the DS phenotype of trisomy all 
Hsa21 orthologs. Given the expense, and failures, of clinical trials for ID in DS, devoting time 
and effort to understanding molecular correlates may be advantageous. 
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Table 1. Biological meaning of between-group comparisons 
 
Comparison Groups MWM performance  
A Ts65Dn-vehicle vs. control-vehicle Failed vs. Normal FvN 
B Ts65Dn-RO4938581 vs. Ts65Dn-
vehicle 
Rescued vs. Failed RvF 
C Ts65Dn-RO4938581 vs. control-
vehicle 
Rescued vs. Normal RvN 
D Control-RO4938581 vs. control-
vehicle 
Normal-RO4938581 vs. 
Normal 
NRvN 
MWM, Morris Water Maze. F, failed MWM performance; R, rescued MWM performance; N and NR (vehicle 
treated) and (RO4938581 treated) normal performance in the MWM. 
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Table 2. Numbers and magnitudes of protein differences between groups 
 
 # protein differences Magnitudes of differences (increases, decreases) 
 Total Increased Decreased <20% 20%-30% 30%-50% >50% 
FvN 52 28 24 4,18 13,5 8,1 3,0 
RvF 57 19 38 11,9 7,21 1,8 0,0 
RvN 10 2 8 2,4 0,3 0,1 0,0 
NRvN 13 9 4 9,2 0,2 0,0 0,0 
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Table 3. Expression differences in functional classes 
 MAPK 
(19) 
MTOR 
(15) 
NMDAR 
(16) 
AD-related 
(12) 
IEG 
(4) 
Apoptosis 
(5) 
FvN 10 6 12 6 2 4 
RvF 9 9 8 8 3 4 
RvN 3 1 0 2 0 1 
NRvN 5 3 4 1 0 0 
Proteins within each class are listed in Appendix B (available from the authors). See also Figure 3 for NMDAR and 
related proteins. 
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Table 4. Signaling pathway perturbations (column 1) and responses after RO4938581 treatment 
(columns 2-4) in MAPK and MTOR pathway components.   
 1 2 3 4 
 FvN RvF RvN NRvN 
MAPK pathway 
BRAF 25% -31% -14% -16% 
ERK 37% -24%   
pERK 20% -37% -24% -23% 
RSK -16% 24%  17% 
pRSK 37% -36%   
PKCA -10% 17%   
MTOR pathway 
AMPKA 35% -33%   
AKT 47% -27%   
pAKT  -25% -27%  
pS6 42% -37%  -20% 
RAPTOR 17% -17%   
GSK3B  -16%   
pGSK3BS9 -11%    
pGSK3BY212  13%  11% 
pEIF4B -18% 20%  11% 
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Table 5. Perturbations and responses to RO4938581 treatment of IEG, histone H3 modifications 
and a subset of AD-related proteins. 
 FvN RvF RvN NRvN  FvN RvF RvN NRvN 
IEGs AD-related 
ARC     APP 59% -29% 13%  
CFOS -14% 20%   pTAU 26% -26%   
pCFOS 18% -22%   ERBB4  -14% -17% -26% 
ERG1  -20%   pSRC -16% 15%   
Histone modifications CHAT 22% -16%   
H3AcK18  -37% -28%  IL1B 49% -20%   
H3AcK9  -29% -19%       
 
  
  
37 
 
Table 6. Numbers of correlations for selected proteins.  
Protein V/R Control Common Ts65Dn 
NR1 V 0 3 9 
 R 0,5 0,0 0,2 
NR2A V 2 6 10 
 R 0 1,0 1,1 
NR2B V 1 4 9 
 R 0,2 1,0 3,2 
pNR1 V 2 5 12 
 R 0 2 1,3 
pNR2A V 4 0 0 
 R 0,1 1,1 5 
pNR2B V 0 4 14 
 R 0,3 0 5,4 
pGLUR2 V 1 3 16 
 R 2,3 2,5 0,0 
GLUR3 V 6 0 0 
 R 1,8 0,6 0,0 
GLUR4 V 3 0 0 
 R 1,4 0,3 0,4 
PP2A V 4 4 18 
 R 1,3 3,7 (C); 
5,5 (T) 
1 
GAD2 V 1 0 1 
 R 1,2  6,0 4,0 
BDNF V 1 0 8 
 R 1,0 0,1 2,5 
CFOS V 2 2 16 
 R 1,3 1,1 0,0 
RSK V 4 2 2 
 R 1,3 1,8 1,1 
V, vehicle treated; R, RO4938581 treated. In R, the # correlations seen in vehicle treated mice still present in drug 
treated mice and the # of new correlations are separated by commas. 
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Figure legends 
Figure 1. RO4938581 improved Morris Water Maze performance in Ts65Dn mice. Data are 
presented as means ± S.E.M. of the latency to reach the platform during the twelve acquisition 
sessions by the four groups of mice. Data are pooled from Set 1 and Set 2 mice (data from Set 1 
mice were from Martinez-Cue 2013). TS, Ts65Dn; CO, euploid controls.  **: p<0.01; ***: 
p<0.001 TS vs. CO; #: p<0.05; ##: p<0.01 vehicle vs. RO4938581, Bonferroni post hoc tests 
after significant RM ANOVAS (ANOVA ‘genotype’: F(1,39)=48.72, p<0.001; ‘treatment’: 
F(1,39)=0.17, p=0.17; ‘genotype x treatment’: F(1,39)=6.35, p=0.016), i.e. there is a clear effect 
of genotype: Ts65Dn perform less well than euploid controls regardless of treatment. 
 
Figure 2. Venn diagram showing the numbers of proteins that differed between genotypes and/or 
responded to drug treatment. A total of 91 proteins were measured; 23 proteins showed no 
change or difference in any comparison. Numbers within each circle and marked by arrows to 
each circle indicate the number of proteins of the total measured that changed or differed in each 
comparison. A. FvN, failed vs. normal learning/memory (LM): vehicle-treated Ts65Dn vs. 
vehicle-treated control. B. RvF, rescued vs. failed LM: RO4938581-treated Ts65Dn vs. vehicle-
treated Ts65Dn. C. RvN, rescued vs. normal LM: RO4938581-treated Ts65Dn vs. vehicle-
treated controls. D. NRvN, normal LM + RO4938581 vs. normal LM + vehicle. ↑, increased; ↓, 
decreased in comparison. Information in the box at the left could not be included without 
increasing the complexity of the Venn diagram. Changes/differences in 44 proteins are in 
opposite directions in comparisons A and B. 
 
Figure 3. Magnitudes of differences and changes in levels of Hsa21 proteins (A-D) and NMDAR 
and related proteins (E-H) in each genotype/treatment group comparison. The % difference 
between groups is shown on the y-axis. The same proteins are presented in the same order in 
panels A-D and in panels E-H. Black bars, differences ≥10%, significant by 3-level mixed 
effects model with Benjamini-Hochberg correction for multiple testing, p<0.05, and FDR=5%. 
White bars, differences are not significant by the same criteria. 
 
Figure 4. Examples of scatter plots from correlation analysis. Signal intensities for each of the 15 
measurements (from 3 replicates of a 5 point dilution series) for each sample with each antibody 
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were normalized to the corresponding total protein levels and reduced to the mean for each 
sample. Selected pairs of proteins are shown with the Spearman Correlation values, r and p, in 
each graph. Criteria for significance: r>|0.08|, p<0.05. A-D, pNR1 vs. pNR2A in the 4 genotype-
treatment groups: only the control + drug group fails to meet criteria for a significant correlation. 
E,F, GAD2 vs. PP2A in RO4938581 treated mice. G, DYRK1A vs. RCAN1 in control + vehicle 
mice: data cluster in two groups, mice with low values of both proteins and those with high 
values of both proteins. H, pNR2A vs. CFOS: data fail to show a monotonic relationship 
between the two proteins. 
 
Figure 5. Networks of correlations involving NMDAR subunits. Pairwise correlations between 
protein levels were determined by Spearman correlation analysis; selected proteins with r>|0.80| 
and p<0.05 are shown. Correlations present in A: vehicle-treated euploid and Ts65Dn; B: 
RO4938581-treated euploid mice; and C: RO4938581-treated Ts65Dn. Solid lines, correlations 
common to euploid and Ts65Dn mice. Dotted lines, correlations specific to euploid mice. 
Dashed lines, correlations specific to Ts65Dn. Shaded nodes, proteins involved in correlations 
common to euploid and Ts65Dn treated with vehicle. 
 
Figure 6. Networks of correlations involving the protein phosphatase PP2A, regulatory subunit 
PPP2R1A. Pairwise correlations between protein levels were determined by Spearman 
correlation analysis; selected proteins with r>|0.80| and p<0.05 are shown. Correlations present 
in A: vehicle-treated euploid and Ts65Dn, and B: RO4938581-treated euploid and Ts65Dn mice. 
Solid lines, correlations common to euploid and Ts65Dn mice. Dotted lines, correlations specific 
to euploid mice. Dashed lines, correlations specific to Ts65Dn. Shaded nodes, proteins present in 
vehicle and RO4938581 treated mice. 
 
Figure 7. LTP pathway abnormalities in the Ts65Dn treated with vehicle (FvN) and treated with 
RO4938581 (RvN). The LTP pathway schematic was obtained from the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) database; components and relationships between components are 
indicated by red rectangles and red arrows, respectively. Protein interactions with LTP pathway 
components were retrieved from the Human Protein Reference Database (HPRD), and the 
BioGRID and IntAct databases; interactors with evidence of expression in brain (Allen Brain 
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Atlas) were added to the pathway, as indicated by black ovals and black dotted lines. Proteins 
measured by RPPA are color coded: grey, no difference in FvN or RvN; yellow, different in 
FvN; green, different in RvN. For simplicity, a single node represents all forms measured of a 
single protein (both modification-independent and dependent). For magnitudes and directions of 
protein/protein modification differences specific to each node, see Appendix C. 
 
Figure 8.  Heat maps comparing protein abnormalities and responses to two drug treatment 
protocols. In each heatmap, lane 1: Ts65Dn vs. euploid controls (whole hippocampal lysates) 
after the behavioral battery and exposure to the MWM, plus vehicle or RO4938581; lanes 2 and 
3: Ts65Dn vs. euploid controls (membrane, cytosol or nuclear subcellular fractions) after 
exposure to CFC (context-shock groups), plus saline or memantine (details are provided in 
Ahmed et al.. 2014, 2015). FvN: Ts65Dn failed LM vs. euploid control normal LM (vehicle or 
saline); RvN: Ts65Dn rescued LM (RO4938581 or memantine) vs. euploid control (vehicle or 
saline) normal LM. Separate heatmaps are shown to compare data obtained from whole 
hippocampal lysates with data obtained from subcellular fractions (A) cytosol and membrane and 
(B) cytosol and nuclear. (A) lane 1, whole hippocampal lysates; lanes 2 and 3, cytosol and 
membrane fractions, respectively. (B) lane 1, whole hippocampal lysates; lanes 2 and 3, nuclear 
and cytosol, respectively. Yellow, increased; blue, decreased; black, unchanged; grey, not 
measured or no expression detected. 
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Appendix A. Information for individual mice. Mouse #, experimental animals; littermates, indicates animals housed together (not 
all littermates were experimental animals). Age, at sacrifice. 
Set Mouse # Littermates Age Genotype Treatment 
1 97 98,99,100  6 months Control vehicle 
1 101 102,103  6 months Ts65Dn vehicle 
1 108 106,107  5 months and 3 weeks Control RO4938581 
1 110 109,111  5 months and 3 weeks Control vehicle 
1 111 109,110 5 months and 3 weeks Control vehicle 
1 114 112,113 5 months and 3 weeks Ts65Dn vehicle 
1 115 116 5 months and 3 weeks Ts65Dn vehicle 
1 126 125,127,128 5 months and 2 weeks Control RO4938581 
1 127 125,126,128 5 months and 2 weeks Ts65Dn RO4938581 
1 149 148,150 6 months Ts65Dn RO4938581 
1 151 152,153,154 6 months Control RO4938581 
1 154 151,152,153 6 months Ts65Dn RO4938581 
1 157 155,156 5 months and 3 weeks Ts65Dn RO4938581 
1 158 159,160,161 5 months and 2 weeks Control RO4938581 
1 162 163,164,165 5 months and 2 weeks Control RO4938581 
1 180 181,182,183 5 months  Control vehicle 
1 187 188,189,190 5 months Ts65Dn vehicle 
1 189 187,188,190 5 months Ts65Dn vehicle 
1 191 192,193 5 months Control vehicle 
2 725 727 6 months and 1 week Ts65Dn vehicle 
2 728 729,730,731 6 months and 1 week Control vehicle 
2 737 738,739 6 months Ts65Dn vehicle 
2 738 737,739 6 months Control vehicle 
2 740 741,742 6 months Ts65Dn RO4938581 
2 741 740,742 6 months Control vehicle 
2 742 740,741 6 months Ts65Dn RO4938581 
2 747 746 5 months and 3 weeks Control RO4938581 
2 748 751,752 5 months and 3 weeks Ts65Dn vehicle 
2 753 754,755,756 5 months and 3 weeks Control vehicle 
Appendix A
  
 2 754 753,755,756 5 months and 3 weeks Ts65Dn vehicle 
2 755 753,754,756 5 months and 3 weeks Control RO4938581 
2 757 758,759,760 5 months and 2 weeks Ts65Dn RO4938581 
2 758 757,759,760 5 months and 2 weeks Ts65Dn vehicle 
2 759 757,758,760 5 months and 2 weeks Control vehicle 
2 760 757,758,758 5 months and 2 weeks Ts65Dn RO4938581 
2 761 762,763 5 months and 2 weeks Control RO4938581 
2 763 761,762 5 months and 2 weeks Control vehicle 
2 767 765,766,768 5 months and 1 week Control RO4938581 
2 769 770,771,772 5 months Ts65Dn vehicle 
2 771 769,770,772 5 months Control vehicle 
2 772 769,770,771 5 months Control RO4938581 
2 773 774,775,776 5 months Ts65Dn RO4938581 
2 776 773,774,775 5 months Ts65Dn RO4938581 
  
Appendix B. Protein and antibody information. All proteins are included, with common and official names and chromosome location (human/mouse). 
Functional class: ID, mutation in the human gene results in intellectual disability (Sturgeon et al 2012). LM, SP and ST: mutation of the mouse gene results 
in abnormal learning/memory, synaptic plasticity and synaptic transmission, respectively (information from the Mammalian Phenotype Browser, 
http://www.informatics.jax.org/searches/MP_form.shtml); Y, yes. Other: if not Hsa21: MAPK, protein is a component mitogen activated protein kinase 
pathawy; MTOR: protein is a component of the mechanistic target of rapamycin pathway; apoptosis, protein functions in apopotosis; IEG, immediate early 
gene; AD, reported abnormal in brains of patients with Alzheimer’s Disease or mouse models of AD (see references in Table 1, Block et al 2014). 
Common protein 
name 
Official 
name 
 Functional class Antibody Source Catalogue # Dilution 
chr ID LM SP ST Other 
ADARB1 ADARB2 21/10    Y HSA21 Aviva Systems Biology ARP40342_T100 1:500 
AKT AKT1 14/12    Y MTOR Santa Cruz Biotechnology SC-1619 1:300 
AMPKA PRKAA1 5/15     MTOR Cell Signaling 2532 1:750 
APP APP 21/16  Y  Y AD Cell Signaling 2452 1:300 
ARC ARC 8/15  Y  Y IEG Abcam Ab118929 1:300 
BAD BAD 11/19     Apoptosis Cell Signaling 9292 1:500 
BAX BAX 19/7     Apoptosis Cell Signaling 2772 1:750 
BCL2 BCL2 18/1     Apoptosis Cell Signaling 2870 1:500 
BDNF BDNF 11/2  Y Y Y AD Epitomics 2960-1 1:500 
BRAF BRAF 7/6 Y Y  Y MAPK Cell Signaling 9434 1:500 
CAMKII CAMK2 5/18  Y Y Y MAPK Cell Signaling 3362 1:500 
CaNA PPP3CA 4/3     AD Cell Signaling 2614 1:1000 
Catalase 
CAT 11/2     Oxidative 
stress Abcam 
Ab50434 
1:500 
CASP3 CASP3 4/8  Y Y Y Apoptosis; AD Cell Signaling 9662 1:500 
CCT8 
CCT8 21/16     HSA21 
Aviva Systems Biology 
ARP45837_P050 
1:1000 
CDK5 CDK5 7/5  Y  Y AD Cell Signaling 2506 1:500 
cFOS CFOS 14/12  Y  Y IEG Cell Signaling 2250 1:300 
CHAF1B CHAF1B 21/16     HSA21 Aviva Systems Biology  ARP45826_P050 1:750 
CHAT CHAT 10/14     AD Millipore AB1442 1:300 
CREB CREB1 2/1  Y  Y MAPK Cell Signaling 9197 1:500 
DONSON DONSON 21/16     HSA21 Aviva Systems Biology ARP45862_P050 1:1000 
DYRK1A DYRK1A 21/16 Y    HSA21 Abnova H00001859-M01 1:750 
EGR1 EGR1 5/18  Y   IEG Cell Signaling 4154 1:300 
ERBB4 ERBB4 2/1  Y  Y AD Protein Technology 19943-1-AP 1:300 
ERK1/2 
MAPK1/3 22/16, 
16/7 
 Y  Y MAPK 
Santa Cruz Biotechnology 
SC-153 
1:300 
ETS2 ETS2 21/16     HSA21 Aviva Systems Biology APR38592_P050 1:500 
FTCD FTCD 21/10 Y    HSA21 Aviva Systems Biology APR41577_P050 1:1000 
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FYN FYN 6/10  Y  Y AD Cell Signaling 4023 1:500 
GAD2 GAD2 10/2      Cell Signaling 3988 1:1000 
GFAP GFAP 17/11 Y Y  Y AD Epitomics 2301-1 1:500 
GluR3 GRIA3 X/X Y   Y iGlut Cell Signaling 5117 1:750 
GluR4 GRIA4 11/9  Y  Y iGlut Cell Signaling 3824 1:300 
GSK3B GSK3B 3/16  Y  Y MTOR; AD BD Biosciences 610201 1:3000 
HistoneH3 
(AcK18) 
HIST3H3 1/ Y    Histone 
modification Cell Signaling 
9675 
1:300 
HistoneH3 (AcK9) 
HIST3H3 1/ Y    Histone 
modification Cell Signaling 
9649 
1:300 
HistoneH3 
(DMeK4) 
HIST3H3 1/ Y    Histone 
modification Cell Signaling 
9725 
1:300 
IL1B IL1B 2/2     AD Abnova H00003553 1:3000 
ITSN1 ITSN1 21/16     HSA21 BD Biosciences 611574 1:1500 
JNK MAPK8 10/14     MAPK Cell Signaling 9252 1:500 
MEK1/2 
MAP2K1/2 15/9, 
19/10 
Y    MAPK 
Cell Signaling 
9122 
1:500 
MTOR MTOR 1/4     MTOR Cell Signaling 2972 1:500 
nNOS NOS1 12/5  Y  Y AD Cell Signaling 4234 1:500 
NR1 GRIN1 9/2 Y Y Y Y AD; iGlut Upstate Biotechnology 07-362 1:500 
NR2A GRIN2A 16/16 Y Y  Y AD; iGlut PhosphoSolutions 1497-NR2A 1:500 
NR2B GRIN2B 12/6 Y Y Y Y AD;iGlut PhosphoSolutions 1498-NR2B 1:500 
NUMB NUMB 14/12     AD Cell Signaling 2756 1:500 
P35/25 CDK5R1 17/11  Y  Y AD Cell Signaling 2680 1:750 
P38 MAPK14 6/17     MAPK Cell Signaling 9212 1:500 
P70S6 RPS6KB1 17/11     MTOR Santa Cruz Biotechnology SC-8418 1:400 
pAKT (Ser473) AKT1 14/12    Y MTOR Cell Signaling 4060 1:500 
pBRAF(Thr401) BRAF 7/6 Y Y  Y MAPK Epitomics 2298-1 1:1000 
Thr286) 
CAMK2A/B 5/18  Y Y Y MAPK 
PhosphoSolutions 
p1005-286 
1:4000 
pCASP9(Ser196) CAPS9 1/4     Apoptosis Abgent AP3044a 1:300 
pcFOS CFOS 14/12  Y  Y IEG Cell Signaling 5348 1:300 
pCREB( Ser133) CREB1 2/1  Y  Y MAPK PhosphoSolutions p1010-133 1:500 
pEIF4B(Ser422) EIF4B 12/15     MTOR Cell Signaling 3591 1:500 
pELK1 (Ser383) ELK1 X/X     MAPK Santa Cruz Biotechnology SC-8406 1:500 
pERK1/2(Tyr204) 
MAPK1/3 22/16,
16/7 
 Y  Y MAPK 
Santa Cruz Biotechnology 
SC-7383 
1:500 
pGJA1 (Ser368)  6/10      Abnova PAB9652 1:500 
  
pGluR2(Tyr876) GRIA2 4/3  Y Y Y iGlut Cell Signaling 4027 1:500 
pGSK3B(Ser9) GSK3B 3/16  Y  Y MTOR; AD Cell Signaling 9323 1:750 
pGSK3B
) 
GSK3B 3/16  Y  Y MTOR; AD 
BD Biosciences 
612312 
1:2000 
PI3K PIK3CA 3/3     MTOR Cell Signaling 4249 1:500 
pJNK(Thr183/Tyr
185) 
MAPK8 10/14     MAPK 
Cell Signaling 
9251 
1:1000 
PKCA PRKCA 17/11     MAPK Cell Signaling 2056 1:500 
pMEK1/2(Ser217/
221) 
MAP2K1/2 15/9, 
19/10 
Y    MAPK Cell Signaling 9154 1:750 
pMTOR(Ser2448) MTOR 1/4     MTOR Cell Signaling 2971 1:500 
pNR1(Ser889) GRIN1 9/2 Y Y Y Y AD; iGlut Epitomics 2329-1 1:500 
pNR2A(Tyr1246) GRIN2A 16/16 Y Y  Y AD; iGlut Cell Signaling 4206 1:500 
pNR2B(Tyr1336) GRIN2B 12/6 Y Y Y Y AD; iGlut PhosphoSolutions p1516-1336 1:500 
pNUMB(Ser276) NUMB 14/12     AD Cell Signaling 4140 1:500 
PP2A PPP2R1A 19/17     AD Cell Signaling 2041 1:750 
pP70S6(Thr389) RPS6KB1 17/11     MTOR Cell Signaling 9205 1:500 
pPKCA/B(Thr638/
641) 
PRKAA/B 17/11     MAPK 
Cell Signaling 
9375 
1:750 
pPKCG (Thr514) PRKCAG 17/11 Y Y  Y MAPK Cell Signaling 9379 1:750 
PRMT2 PRMT3 21/10     HSA21 Aviva Systems Biology ARP40196_T100 1:2000 
pRSK(Ser380) RPS6KA3 X/X Y    MAPK Cell Signaling 9341 1:500 
pS6(Ser240/244) RPS6 9/4     MTOR Cell Signaling 5364 1:500 
PSD95 DLG4 17/11  Y  Y AD Cell Signaling 3450 1:1000 
pSRC(Tyr416) FYN 6/10  Y  Y AD Cell Signaling 6943 1:500 
pTau (Thr212) MAPT 17/11  Y  Y AD Invitrogen 44740G 1:3000 
RAPTOR RPTOR 17/11     MTOR Cell Signaling 2280 1:750 
RCAN1 RCAN1 21/16     HSA21 Sigma-Aldrich D6694 1:2000 
RRP1 RRP1 21/10     HSA21 Aviva Systems Biology ARP45812_P050 1:2000 
RSK2 RPS6KA3 X/X Y    MAPK Cell Signaling 9340 1:300 
S6 RPS6 9/4     MTOR Cell Signaling 2217 1:500 
SHH 
SHH 7/5 Y    Sonic 
Hedgehog Cell Signaling 
2207 
1:500 
SOD1 SOD1 21/16     HSA21 Santa Cruz Biotechnology SC-11407 1:500 
STAT3 STAT3 17/11     JAK-STAT Cell Signaling 9139 1:500 
SYP SYP X/X Y    AD Epitomics 1870-1 1:5000 
Tau MAPT 17/11  Y  Y AD Cell Signaling 4019 1:500 
TH TH 11/7 Y Y   AD Cell Signaling 2792 1:750 
TIAM1 TIAM1 21/16     HSA21 Abcam Ab54458 1:1500 
  
TRKA NTRK1 1/3 Y Y   AD Epitomics 2244-1 1:2000 
Ubiquitin UBC 12/5     Ubiquitination Cell Signaling 3933 1:1000 
 SNCA 4/6    Y AD Cell Signaling 4179 1:3000 
-Catenin CTNNB1 3/9 Y    AD Cell Signaling 9562 1:1000 
 
  
3LME results3-level mixed effects results protein measurements
Protein VehicleTs65Dn vs controlPValue Error StepdownBonferroniAdaptiveHochbergFDR Protein Control RO4938581 vs vehiclePValue Error StepdownBonferroniAdaptiveHochbergFDR
ADARB1 1.04E+01 6.28E-02 5.27E+00 1.00E+00 5.66E-01 8.17E-02 ADARB1 -1.41E+01 1.98E-03 4.80E+00 1.46E-01 9.70E-02 9.36E-03
AKT 4.73E+01 6.34E-11 5.63E+00 4.82E-09 5.71E-10 3.61E-10 AKT 6.30E+00 2.69E-01 5.51E+00 1.00E+00 9.63E-01 4.37E-01
AMPKA 3.46E+01 4.82E-14 3.65E+00 4.00E-12 4.34E-13 4.46E-13 AMPKA -4.49E+00 2.66E-01 4.12E+00 1.00E+00 9.63E-01 4.37E-01
APP 5.93E+01 2.62E-44 2.56E+00 2.39E-42 2.36E-43 2.39E-42 APP -5.06E+00 8.09E-02 2.96E+00 1.00E+00 9.63E-01 1.71E-01
ARC 2.69E+00 6.16E-01 5.28E+00 1.00E+00 9.87E-01 6.37E-01 ARC -1.27E+01 3.72E-03 4.61E+00 2.57E-01 1.82E-01 1.47E-02
BAD 3.26E+01 6.48E-18 2.95E+00 5.77E-16 5.83E-17 1.97E-16 BAD -1.60E+00 7.01E-01 4.20E+00 1.00E+00 9.63E-01 8.62E-01
BAX 2.53E+01 2.26E-17 2.45E+00 1.99E-15 2.03E-16 5.14E-16 BAX -7.51E+00 5.85E-03 2.80E+00 3.86E-01 2.87E-01 2.05E-02
BCL2 2.13E+01 1.83E-09 3.05E+00 1.32E-07 1.65E-08 8.34E-09 BCL2 -7.07E+00 8.98E-02 4.30E+00 1.00E+00 9.63E-01 1.82E-01
BDNF -1.37E+01 1.85E-08 2.50E+00 1.31E-06 1.66E-07 8.00E-08 BDNF -9.16E+00 1.76E-03 3.02E+00 1.32E-01 8.60E-02 9.36E-03
BRAF 2.52E+01 3.15E-12 3.04E+00 2.49E-10 2.83E-11 2.20E-11 BRAF -1.56E+01 1.17E-06 3.37E+00 1.04E-04 5.71E-05 3.53E-05
CAMKII -1.07E+01 6.60E-04 3.26E+00 2.77E-02 5.94E-03 1.20E-03 CAMKII 1.60E+01 3.19E-06 3.08E+00 2.80E-04 1.56E-04 7.25E-05
CASP3 2.34E+01 1.76E-11 2.91E+00 1.38E-09 1.59E-10 1.15E-10 CASP3 -1.06E+01 2.84E-03 3.70E+00 1.99E-01 1.39E-01 1.17E-02
CAT -7.54E+00 2.08E-02 3.37E+00 6.23E-01 1.87E-01 3.05E-02 CAT 1.25E+01 1.89E-05 2.68E+00 1.62E-03 9.26E-04 2.87E-04
CDK5 -1.39E+01 1.70E-02 6.23E+00 5.45E-01 1.53E-01 2.58E-02 CDK5 -1.55E+01 2.12E-03 5.43E+00 1.53E-01 1.04E-01 9.36E-03
CFOS -1.35E+01 4.67E-10 2.23E+00 3.41E-08 4.20E-09 2.23E-09 CFOS 6.65E+00 7.70E-04 1.89E+00 6.08E-02 3.77E-02 5.39E-03
CHAT 2.19E+01 2.36E-13 2.53E+00 1.89E-11 2.12E-12 1.79E-12 CHAT 2.12E+00 5.18E-01 3.24E+00 1.00E+00 9.63E-01 6.64E-01
CREB -9.32E+00 4.65E-05 2.35E+00 2.37E-03 4.18E-04 1.03E-04 CREB 1.14E+01 2.14E-04 2.87E+00 1.71E-02 1.05E-02 1.62E-03
CTNNB1 -1.04E+01 3.16E-02 5.09E+00 8.53E-01 2.84E-01 4.42E-02 CTNNB1 2.37E+00 6.21E-01 4.74E+00 1.00E+00 9.63E-01 7.85E-01
DONSON 3.34E+01 1.09E-06 5.68E+00 6.40E-05 9.77E-06 2.99E-06 DONSON 7.19E-01 8.96E-01 5.49E+00 1.00E+00 9.63E-01 9.27E-01
DYRK1A 2.42E+01 1.28E-04 5.52E+00 6.27E-03 1.15E-03 2.71E-04 DYRK1A -4.45E-01 9.38E-01 5.72E+00 1.00E+00 9.63E-01 9.48E-01
EGR1 1.54E+01 4.29E-02 7.03E+00 1.00E+00 3.86E-01 5.91E-02 EGR1 -1.42E+01 9.07E-03 5.79E+00 5.89E-01 4.44E-01 3.06E-02
ELK -4.21E+00 1.93E-01 3.30E+00 1.00E+00 9.87E-01 2.31E-01 ELK -8.70E-01 7.89E-01 3.27E+00 1.00E+00 9.63E-01 8.87E-01
ERBB4 -3.47E+00 4.37E-01 4.54E+00 1.00E+00 9.87E-01 4.79E-01 ERBB4 -2.59E+01 9.23E-13 3.81E+00 8.40E-11 4.52E-11 8.40E-11
ERK 3.65E+01 5.84E-08 5.43E+00 3.91E-06 5.25E-07 2.12E-07 ERK -6.20E+00 3.45E-01 6.75E+00 1.00E+00 9.63E-01 5.27E-01
ETS2 -9.82E+00 1.34E-06 2.08E+00 7.64E-05 1.21E-05 3.48E-06 ETS2 -8.15E-01 7.40E-01 2.46E+00 1.00E+00 9.63E-01 8.74E-01
FYN -7.62E+00 2.78E-01 7.29E+00 1.00E+00 9.87E-01 3.20E-01 FYN 1.71E+00 8.09E-01 7.01E+00 1.00E+00 9.63E-01 8.98E-01
GAD2 -1.14E+01 2.53E-08 2.09E+00 1.74E-06 2.28E-07 1.00E-07 GAD2 5.53E+00 5.78E-02 2.82E+00 1.00E+00 9.63E-01 1.31E-01
GFAP -1.12E+01 6.32E-06 2.56E+00 3.41E-04 5.68E-05 1.51E-05 GFAP 1.05E+01 2.16E-03 3.22E+00 1.53E-01 1.06E-01 9.36E-03
GluR3 -1.04E+01 3.31E-08 1.91E+00 2.25E-06 2.98E-07 1.25E-07 GluR3 1.13E+01 4.17E-05 2.57E+00 3.42E-03 2.04E-03 3.80E-04
GluR4 -2.20E+01 1.51E-13 3.14E+00 1.22E-11 1.36E-12 1.25E-12 GluR4 -2.87E+00 4.44E-01 3.80E+00 1.00E+00 9.63E-01 6.03E-01
GSK3B -4.57E+00 8.96E-02 2.74E+00 1.00E+00 8.07E-01 1.15E-01 GSK3B 1.84E+00 5.02E-01 2.71E+00 1.00E+00 9.63E-01 6.53E-01
H3K18 -1.97E+01 1.39E-04 5.62E+00 6.69E-03 1.25E-03 2.88E-04 H3K18 -5.81E+00 2.58E-01 5.28E+00 1.00E+00 9.63E-01 4.37E-01
H3K27 1.38E+01 1.26E-02 5.11E+00 4.14E-01 1.13E-01 1.94E-02 H3K27 -4.55E+00 3.59E-01 5.06E+00 1.00E+00 9.63E-01 5.36E-01
IL1B 4.89E+01 2.49E-08 6.78E+00 1.74E-06 2.24E-07 1.00E-07 IL1B 1.09E+01 8.87E-02 6.05E+00 1.00E+00 9.63E-01 1.82E-01
ITSN1 5.71E+01 2.61E-10 6.78E+00 1.96E-08 2.35E-09 1.40E-09 ITSN1 -1.21E+00 8.67E-01 7.29E+00 1.00E+00 9.63E-01 9.27E-01
JNK 2.87E+01 7.04E-17 2.77E+00 6.05E-15 6.34E-16 1.07E-15 JNK -9.35E+00 1.05E-03 2.95E+00 8.23E-02 5.17E-02 6.46E-03
MEK -5.48E-02 9.87E-01 3.37E+00 1.00E+00 9.87E-01 9.87E-01 MEK -9.45E-01 7.49E-01 2.97E+00 1.00E+00 9.63E-01 8.74E-01
MTOR 1.01E+01 2.31E-02 4.18E+00 6.70E-01 2.08E-01 3.34E-02 MTOR -5.25E+00 2.64E-01 4.81E+00 1.00E+00 9.63E-01 4.37E-01
NNOS -8.24E+00 3.14E-01 8.51E+00 1.00E+00 9.87E-01 3.53E-01 NNOS -8.82E+00 2.04E-01 7.23E+00 1.00E+00 9.63E-01 3.62E-01
NR1 -2.10E+01 5.72E-07 4.57E+00 3.49E-05 5.15E-06 1.68E-06 NR1 1.24E+01 4.29E-03 4.06E+00 2.92E-01 2.10E-01 1.63E-02
NR2A -2.10E+01 5.95E-06 5.08E+00 3.27E-04 5.36E-05 1.46E-05 NR2A 1.10E+01 2.14E-02 4.49E+00 1.00E+00 9.63E-01 6.10E-02
NR2B -1.95E+01 1.97E-05 4.98E+00 1.02E-03 1.77E-04 4.48E-05 NR2B 9.77E+00 3.98E-02 4.50E+00 1.00E+00 9.63E-01 9.79E-02
NUMB -8.40E+00 5.93E-02 4.63E+00 1.00E+00 5.34E-01 7.82E-02 NUMB -1.35E+00 7.82E-01 4.91E+00 1.00E+00 9.63E-01 8.87E-01
P3525 -8.45E+00 2.04E-03 2.83E+00 8.36E-02 1.84E-02 3.64E-03 P3525 -3.83E+00 1.89E-01 2.96E+00 1.00E+00 9.63E-01 3.44E-01
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Highlights 
• Levels of 91 proteins relevant to brain function were measured in Ts65Dn hippocampus after 
training in the Morris Water Maze 
• Levels of 55 proteins/protein modifications were abnormal in vehicle-treated Ts65Dn compared 
with littermate controls 
• the GABAAα5-selective modulator, RO4938581, that rescues learning deficits, corrected the 
majority of protein abnormalities 
• protein abnormalities, and their correction, are consistent with abnormalities in and rescue of 
LTP 
 
